Thryv Therapeutics to Participate in Upcoming 2025 Healthcare Investor Conferences
PR Newswire —
MONTREAL, Nov. 3, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced...